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abstract

PURPOSE Scalp cooling therapy (SCT) is the most effective method to reduce chemotherapy-induced alopecia
(CIA), a highly distressing side effect of cancer treatment. Despite data supporting SCT efﬁcacy and safety, SCT
use in the United States is not widespread. Oncologists’ interactions with scalp cooling were examined to identify
facilitators and barriers to SCT implementation.
METHODS A 33-question survey was distributed through the ASCO Research Survey Pool to a nationally
representative, random sample of 600 oncology providers. Outcome measures included knowledge of SCT,
frequency of initiating conversations about SCT with patients, degree of support, and barriers for SCT. Signiﬁcance was deﬁned as P , .001.

RESULTS Of 155 (25.8%) responding providers, 62% of providers were in favor of SCT always or most of the time,
but only 26% reported initiating discussions about SCT always or most of the time. Providers who treat breast
cancer (P # .0001), those who report being very familiar with SCT (P # .0001), those who report having read
SCT literature in the past 2 years (P # .0001), and those who work at a facility with machine SCT (P # .0001)
were signiﬁcantly more likely to initiate conversations with patients about SCT. Financial concerns (58%) were
the primary reason for not recommending SCT use; efﬁcacy (31%), staff or facility (24%), and safety (15%)
concerns were also noted. Although safety concerns have decreased markedly over time, 14% of providers
report patients who continue to express these concerns and 17% of providers see safety issues as barriers to
supporting SCT.
CONCLUSION Our ﬁndings suggest that oncology provider familiarity and experience with SCT lead to increased
support for scalp cooling, which may ultimately result in greater availability and utilization of SCT when indicated.
JCO Oncol Pract 00. © 2021 by American Society of Clinical Oncology
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Chemotherapy-induced alopecia (CIA) is a common
and often highly distressing side effect of cancer
therapies.1,2 More than 50% of patients with cancer
have cited CIA as the most feared side effect of
chemotherapy, and up to 8% of women reported that
they would consider declining curative chemotherapy
because of the risk of hair loss.1,2 Different modalities
have been used to decrease hair loss during chemotherapy, including topical minoxidil, oral vitamin
D3, scalp compression, and most recently, scalp
cooling therapy (SCT).3
SCT entails wearing subfreezing head caps before,
during, and after the chemotherapy infusion. It is

postulated to work through two primary mechanisms:
(1) cold-induced vasoconstriction that reduces delivery of chemotherapy to the hair follicles and (2) a
reduced metabolic rate that slows hair cell turnover
and processing of chemotherapy agents.4 There are
two types of scalp cooling equipment: manual capping
systems (cold caps) and machine scalp cooling systems (SCSs). Manual cold caps are typically rented by
the patient, stored in either special freezers at infusion
centers or in dry ice purchased by the patient, and
changed approximately every 25 minutes during
chemotherapy infusion. Machine SCSs are maintained
by the infusion center and deliver a constant coolant to
a scalp cap on the patient’s head.3,4
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Despite guidelines for the appropriate use of SCT in certain
malignancies, including US Food and Drug Administration
clearance of machine SCS, and a growing body of literature
supporting its efﬁcacy and safety, the use of SCT for reducing CIA is not widespread in the United States.5-16 We
hypothesized that both patient- and physician-related
barriers exist that contribute to low uptake of SCT. To
address the paucity of information about facilitators and
barriers in oncology practices to SCT implentation,8,17,18 we
examined oncologists’ knowledge, practice patterns, and
attitudes regarding scalp cooling.
METHODS
We created a 33-question survey to assess provider interactions with SCT. Questions were adapted from a previous survey that analyzed provider perceptions of fertility
preservation.19 The initial survey was piloted with University
of Michigan Hematology Oncology fellows, and questions
were reﬁned on the basis of their feedback. Questions
focused on demographics; facility SCT availability; and
provider knowledge, attitudes, and perceptions of and
practice patterns with SCT (Data Supplement, online only).
The survey was distributed through the ASCO Research
Survey Pool. An e-mail was sent to a nationally representative, random sample of physicians and advanced practice
providers in medical oncology, surgical oncology, gynecology, and urology in February 2020. Reminders were
sent every 2-4 weeks until the survey closed in June 2020.
Responses were anonymous, and no incentives to complete the survey were offered. This study was designated
exempt by the University of Michigan Institutional Review
Board Health Sciences and Behavioral Sciences.
Main outcome measures included the distribution of providers’ knowledge of SCT, frequency of initiating conversations about SCT with patients, and degree of provider
support for its use. The survey also investigated barriers to
support of SCT and scalp cooling options offered at respondents’ institutions. The majority of analyses were descriptive. Chi-square and Fisher’s exact tests were used.
Answer categories were combined for analyses to create
either four groups (1) all of the time and most of the time, (2)
half of the time and some of the time, (3) never, and (4) do
not know enough; or three groups (1) strongly agree and
somewhat agree, (2) neither agree nor disagree, and (3)
somewhat disagree and strongly disagree. Rates of initiating discussions with patients about SCT and being in
favor of SCT were compared between the following groups:
providers who treat breast cancer versus those who do not,
providers who are very familiar with SCT versus those who
have only heard of it, providers who have read literature
versus those who have not, providers who work at institutions that offer scalp cooling versus those who do not, and
providers who strongly or somewhat agree that they have
high concern for their patients’ hair loss versus those who
neither agree nor disagree versus those who somewhat or

strongly disagree with that statement. All data were analyzed using SAS v9.4 (Cary, NC). Using Bonferroni multiple
comparisons correction, signiﬁcance was deﬁned conservatively at P , .001.
RESULTS
Demographics
Of 600 invited providers from the ASCO research survey
pool, 155 responded (25.8%). Provider characteristics are
shown in Table 1. The majority of respondents were
medical oncologists (118 of 155, 76.1%). Breast cancer
was the most commonly treated malignancy (93 of 155,
60.0%). Nearly half of the participants (76 of 155, 49.0%)
worked at a university hospital, and 64.5% (100 of 155) of
providers worked in an urban setting. The largest proportion
of respondents were 45-54 years old. The subset who
responded were representative of the full population invited
to participate regarding sex, ethnicity, region of practice,
specialty, and type of practice.
Provider Knowledge, Practice Patterns, and Attitudes
on SCT
Table 2 characterizes provider knowledge, practice patterns, and attitudes about SCT and facility offerings of SCT.
Among respondents, 52.9% (82 of 155) reported being
very familiar with SCT, 65.8% (100 of 152) reported having
read literature on SCT in the past two years, and 63.9% (99
of 155) were interested in learning more about SCT as a
means to reduce CIA. Providers interested in learning more
about scalp cooling were more likely to be unfamiliar with
SCT compared with those who responded that they were
not interested in learning more (P 5 .0003). Approximately
half of the providers (85 of 155, 54.8%) agreed that the
effects of hair loss on their patients were a major concern.
Providers on average estimated that their female patients
were signiﬁcantly more interested in options to prevent CIA
than their male patients (P # .0001). Forty-four percent of
providers (58 of 132) estimated that . 50% of their female
patients were interested in options to prevent CIA, whereas
9% (8 of 94) estimated that . 50% of their male patients
were interested.
Sixty-two percent (94 of 152) of providers responded that
they were in favor of SCT all or most of the time, and 67.1%
(102 of 152) felt that all patients should be offered SCT.
Thirty-six percent (55 of 152) of responders thought that
“the effort and cost involved [with SCT] were worth the
beneﬁt.” Seventy-three percent of providers (109 of 151)
said that they would support their facility providing SCT.
However, only 26.3% (40 of 152) reported initiating discussions about SCT always or most of the time.
For providers who treat breast cancer (P # .0001), those
who reported being very familiar with scalp cooling
(P # .0001), those who reported having read literature in
the past 2 years about SCT (P # .0001), and those who
work at a facility with machine SCSs (P # .0001) were
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TABLE 1. Demographic Data of Survey Respondents (N 5 155)

Breast cancer

93 (60.0)

Leukemia

53 (34.2)

Lymphoma

66 (42.6)

who report being very familiar with scalp cooling
(P # .0001), who reported reading literature in the past 2
years about SCT (P # .0001), and who worked at a facility
with machine SCSs (P # .0001) were also signiﬁcantly
more likely to be in favor of SCT always or most of the time
(Fig 1B). Providers who reported that they had higher
concern for their patients’ hair loss were more likely to
always or most of the time initiate discussions with their
patients (P 5 .024) and be in favor of SCT (P 5 .003) than
those who responded that they were indifferent or not
concerned with hair loss, although these did not reach
signiﬁcance. There was no statistically signiﬁcant difference between other demographic information and the rate
of initiating conversations with patients about or being in
favor of SCT.

Sarcoma

50 (32.3)

Provider-Reported Barriers and Facilitators to SCT

CNS tumors

44 (28.4)

GI tumors

74 (47.7)

Lung cancer

74 (47.7)

Financial concern for the patient was the most frequently
cited reason why providers did not always initiate conversations with patients about SCT (76 of 131, 58.0%) and
why providers were not always in favor of SCT (57 of 84,
67.9%; Appendix Table A1, online only). Efﬁcacy was the
second most common concern for not initiating the conversation and not being in favor of SCT, reported by 31.3%
(41 of 131) and 42.9% (36 of 84) of providers, respectively.
Financial concern for the hospital (40 of 78, 51.3%) and
staff constraints (39 of 78, 50.0%) were the most frequently
reported reasons for providers to be unsupportive of any
SCT use at their institution.

Respondents

No. (%)

Provider designation
Medical oncologist
Surgical oncologist
Gynecologic oncologist
Urologist

118 (76.1)
7 (4.5)
12 (7.7)
1 (0.6)

Nurse practitioner or physician assistant
Others

16 (10.3)
2 (1.3)

Cancer treated (can choose multiple)

Gynecologic tumors

62 (40.0)

Testicular cancer

54 (34.8)

Prostate cancer

65 (41.9)

Other genitourinary cancers

59 (38.1)

Others

16 (10.3)

Sex
Male

78 (50.3)

Female

77 (49.7)

Years of practice after residency or fellowship
0-5

26 (16.8)

6-10

26 (16.8)

11-20

53 (34.2)

. 20

50 (32.3)

Age, years

When asked about reasons that patients do not use SCT,
69.7% (101 of 145) of providers cited ﬁnancial concerns,
44.1% (64 of 145) responded that patients are not overly
concerned about hair loss, and 13.8% answered that
patients do not use SCT because of safety concerns (Appendix Table A1). Seventy-three percent (62 of 85) and
44.7% (38 of 85) of providers answered that “importance of
hair preservation to patient” and patient sex, respectively,
were the top patient factors that made a provider more likely
to initiate a conversation about SCT.

, 34

0 (0.0)

35-44

45 (29.0)

45-54

47 (30.3)

55-64

36 (23.2)

DISCUSSION

. 64

20 (12.9)

To our knowledge, this is the largest and most comprehensive survey of cancer providers in the United States
regarding perspectives, attitudes, and practice patterns
surrounding SCT. Although the majority of responding
providers agreed that patients should be educated about
the option of scalp cooling (62%), the reported rate of
initiating conversations on SCT was low (26%). Major
barriers to initiating conversations included lack of familiarity with the technology and patient-related ﬁnancial
concerns. Institutional concerns including staff or space
constraints, facility rules about SCT, and hospital-incurred
costs were other barriers to SCT implementation.

Unknown

7 (4.5)

Practice setting
University hospital

76 (49.0)

Community or private

88 (56.8)

Practice location
Urban

100 (64.5)

Suburban

60 (38.7)

Rural

17 (11.0)

signiﬁcantly more likely to always or most of the time initiate
conversations with patients about SCT and less likely to
never initiate conversations (Fig 1A). Similarly, providers

Providers more familiar with scalp cooling (eg, direct experience and reading literature) were signiﬁcantly more

JCO Oncology Practice
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TABLE 2. Physician Knowledge, Practice Patterns, Attitudes, and Perspectives About SCT
Physician Knowledge
Familiarity with SCTa

Very familiar
82 (52.9)

Not very familiar
70 (45.2)

Interested in learning more

Yes
99 (63.9)

No
56 (36.1)

155

Read literature in the past 2 years on SCT

Yes
100 (65.8)

No
52 (34.2)

152

Does SCT increase incidence of scalp metastases

Deﬁnitely yes
2 (1.3)

Probably yes
7 (4.6)

Not familiar
3 (1.9)

Total
155

Might or might not
36 (23.7)

Probably not
83 (54.6)

Deﬁnitely not
24 (15.8)

152

Physician Practice Patterns

Initiate discussion about SCT
Patients raise topic of SCT

In favor of SCT

Always

Most of the time

About half of the time

Sometimes

Never

Not applicableb

Total

14 (9.2)

26 (17.1)

7 (4.6)

52 (34.2)

46 (30.3)

7 (4.6)

152

0 (0)

2 (1.3)

9 (5.9)

99 (65.1)

42 (27.6)

Always

Most of the time

About half of the time

Sometimes

Never

Do not know

42 (27.6)

52 (34.2)

3 (2.0)

27 (17.8)

2 (1.3)

26 (17.1)

152

152

Attitudes and Perceptions
Strongly
agree

Somewhat
agree

Neither agree nor
disagree

Somewhat
disagree

Strongly
disagree

Effects of hair loss on my patients are a major
concern for me

34 (22.5)

51 (33.8)

36 (23.8)

24 (15.9)

6 (4.0)

Effort and cost involved are worth beneﬁt

15 (9.9)

40 (26.5)

39 (25.8)

28 (18.5)

6 (4.0)

All patients should be educated about SCT

56 (37.1)

46 (30.5)

41 (27.2)

7 (4.6)

1 (0.7)

Do not
know

Total
151

23 (15.2)

151
151

Facility Offerings
Does facility offer SCT

Dry ice
45 (29.6)

Freezers
17 (11.2)

Machine
59 (38.8)

In process
11 (7.2)

Does not allow
22 (14.5)

Do not know
34 (22.4)

Total
152

Support for facility providing SCT

Deﬁnitely yes
58 (38.7)

Probably yes
51 (34.0)

Might or might not
19 (12.7)

Probably not
6 (4.0)

Deﬁnitely not
2 (1.3)

Do not know
14 (9.3)

150

Satisfaction with SCT at facility

Deﬁnitely yes
30 (19.9)

Somewhat
40 (26.5)

Needs improvement
27 (17.9)

Deﬁnitely not
18 (11.9)

Do not know
36 (23.8)

151

NOTE. Data are shown as No. (%).
Abbreviation: SCT, scalp cooling therapy.
a
Complete wording of answer choices to this question on the provider survey included (1) Yes, I am very familiar with these options; (2) Yes, I have heard of
these options, but I am not very familiar with them; and (3) No, I am not familiar with these options.
b
Not applicable means that none of my patients are appropriate candidates for scalp cooling.

likely to initiate SCT conversations with patients and to
support SCT use. A 2018 qualitative study on barriers to
scalp cooling showed that presenting physicians with
clinical data on SCT led to an increase in the frequency
of discussions with patients for physicians who are
initially reluctant.8 Lack of provider familiarity has also
been cited as a barrier for adoption of other cancer-related
procedures, including pretreatment fertility preservation,
despite supportive published guidelines.19 An oncofertility
program focused on provider education and multidisciplinary collaboration resulted in a signiﬁcant increase in
fertility preservation discussions.20 A similar approach
focusing on either physician-directed learning or short

training programs should be considered to increase uptake of SCT.
Our survey showed that, with an average cost of $1,500$3,000 US dollars for a course of chemotherapy, ﬁnancial
concerns are primary barriers to adoption of SCT, a ﬁnding
that is consistent with previous reports.8,18,21 SCT is not
generally covered by medical insurance, so patients must
pay out-of-pocket or seek philanthropic support. New longterm support options to facilitate widespread adoption are
needed.18,22
In contrast to previous studies, which reported that safety of
SCT was a concern,8,18 the majority of providers in this

4 © 2021 by American Society of Clinical Oncology
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A

Always or most of the time

Half or sometimes

Never

P < .0001*

P < .0001*

Do not know enough
P < .0001*

P < .0001*

100
90

13

21

15

17

80

Percent

40

70

56

50

38

45
31

60

40

42

50
40
44

30
20

33
46

40

49

37
38

36

10
12

Very Familiar
With SCT

Not Very
Familiar
With SCT

B

Read Literature Did Not Read
About SCT in Literature About
the Past 2 Years SCT in the Past
2 Years

Always or most of the time
P < .0001*

100

Works at
Did Not Work
Institutions With at Institutions
Machine SCT
With Machine
SCT

Half or sometimes

Never

P < .0001*

1

20

17
21

Does Not Treat
Breast Cancer

Do not know enough
P = .004

3

6

36

Treats Breast
Cancer

P < .0001*

90
80

12

4

3

0

9
26

39

30
21

Percent

70
22

60

18

20
17

50
40

77

78

72

68

30
52

52
44

20

42

10
0
Very Familiar
With SCT

Not Very
Familiar
With SCT

Read Literature
Did Not Read
About SCT in Literature About
the Past 2 Years SCT in the Past
2 Years

Works at
Did Not Work
Institutions With at Institutions
Machine SCT
With Machine
SCT

Treats Breast
Cancer

Does Not Treat
Breast Cancer

FIG 1. Summary of respondent answers related to frequency of (A) initiating conversations about SCT with patients and (B) being in favor of SCT by
answering between the following answer choices: always or most of the time, about half of the time or sometimes, never, or do not know. SCP, scalp cooling
therapy.

survey (70%) agreed that SCT probably or deﬁnitely does
not cause increased incidence of scalp metastases. Only
15% of respondents cited safety concerns as major barriers
for initiating discussions with patients about SCT, and only
17% reported not being in favor of SCT because of safety
issues. This contrasts previous studies that reported safety

concerns as one of, if not, the top reasons to not use or
recommend SCT.8,18 This shift in provider attitudes is consistent with recent literature supporting the safety of SCT.10,23-28
Multiple studies have reported no cases of scalp metastases
with up to 5 years of patient follow-up.26,28 In addition, a relatively recent systematic review and meta-analysis of
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1,959 patients who used SCT and 1,238 who did not use SCT
failed to demonstrate a signiﬁcant difference in the incidence
of scalp metastases (0.61% v 0.41%; P 5 .43).10
Some safety concerns remain, however, and may affect
patient use of SCT as 13% of providers reported that their
patients do not use SCT because of safety concerns. Of
note, the US Food and Drug Administration has not cleared
SCT in patients with hematologic malignancies.29,30 Further
research with long-term follow-up is needed to corroborate
strong existing safety data of SCT and for provider education and reassurance, especially in patients being treated
with curative intent for their malignancies.
Just under half of the providers expressed concern about
efﬁcacy of SCT (43%), consistent with previous studies.8,18
Importantly, recent studies have demonstrated successful
hair preservation with SCT, generally deﬁned as , 50% hair
loss and not requiring a wig.2,10,12,31,32 In a recent systematic review, scalp cooling signiﬁcantly reduced the
relative risk of alopecia by 43% (P , .00001).33 In a
randomized control trial of machine scalp cooling, half of
the patients with breast cancer who used SCT had successful hair preservation versus none of the women in the
control group.9 Similar results were found in a prospective
cohort study with two thirds with successful results versus
none in the control group.31 Providers must also be
reminded that 100% hair loss prevention is not needed as
up to 50% loss of scalp hair is generally not aesthetically
appreciated.9

Providers at institutions where machine SCT is established
were found to be more likely to offer scalp cooling (49% v
12%), but many providers in our survey cited ﬁnancial
concerns (51.3%), in addition to staff and space constraints (50.0%), as barriers to SCT adoption. Nursing
constraints and change to workﬂows were found to be a
signiﬁcant barrier in previous studies.8,18 Some institutions
have published details about the development of their scalp
cooling workﬂows, which combine efforts of providers and
nurses to treat CIA, providing successful strategies for SCT
adoption for other institutions.36,37
Multiple studies have chronicled the adverse psychosocial
effects of CIA on both men and women, with reports of at
least 50% of patients deﬁning hair loss as one of their most
feared chemotherapy-related side effects.6,38-43 We found
that more than 40% of surveyed providers stated that
patients do not use SCT because of not being overly
concerned about hair loss and may initiate these conversations principally in women and patients with breast
cancer. These ﬁndings highlight the need to expand SCT to
a broader population and to not limit discussions of SCT by
patient characteristics, including sex or cancer type.
Our study was limited by a 25% response rate and may be
due to the timing of distribution of the survey at the onset of
the COVID-19 pandemic. Respondents were generally
representative of the total survey population.

In our study, providers more familiar with scalp cooling
(eg, literature and experience) were more likely to be in
favor of SCT and willing to discuss it with patients ostensibly because of the positive results in the literature or
favorable experience with scalp cooling. It is important to
recognize that efﬁcacy varies on the basis of multiple
factors.34 For example, patients treated at institutions
with more experience with SCT have less alopecia,
whereas those treated with anthracyclines have more
alopecia.31 Future research should be directed at modiﬁable factors that affect the effectiveness of SCT, such as
chemotherapy regimen, capping technique, and manual
versus machine SCSs.5,35

In conclusion, to our knowledge, this is the largest study to
address provider interaction, knowledge, and perspectives
with scalp cooling within the United States. Although the
majority of surveyed providers reported feeling favorably
toward scalp cooling, rates of initiating conversations about
SCT with patients were low (24%). Our ﬁndings suggest the
need for physician education and exposure to SCT, through
either physician-directed learning or short training programs, and clear institutional guidelines for the use of SCT.
Although further research on efﬁcacy and safety and
continuous efforts to expand insurance coverage will be
imperative for SCT to become widespread, physicians and
allied health professionals should be educated on SCT, with
the goal of increasing rates of patient education and access
to this important treatment option.
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APPENDIX

TABLE A1. Provider-Reported Reasons for (1) Not Initiating Discussions With Patients About SCT or (2) Not Being in Favor of SCT and Provider Perspectives
on Why Patients Do Not Use SCT
Provider-Reported Reasons for Not Recommending SCT
Providers Who Either Do Not Initiate Discussions on SCT or Who Are Not in
Favor of SCT Cited the Following Reasonsa

Providers Not Initiating Discussions (%)b

Providers Not Being in Favor (%)c

Financial concern for patients

58

67.9

Efﬁcacy concerns

31.3

42.9

Staff constraints

23.7

28.6

Facility does not offer

23.7

19

Do not remember to bring it up

22.1

—

Do not know enough/limited knowledge

20.6

10.7

Safety concerns

15.3

16.7

Too much time to discuss in clinic

11.5

13.1

Do not believe patient interested

11.5

23.8

Space constraints

10.7

10.7

Side effects

9.2

17.9

Too much time in infusion room

9.2

3.6

Other

7.6

2.4

Financial concern for hospital

—

7.1

Providers Perspectives on Why Patients Do Not Use SCT
Providers Cited the Following Reasons That Patients Do Not Use SCT

Provider Responses, No. (%)

Financial concerns

101 (69.7)

Not overly concerned about hair loss

64 (44.1)

Unaware of option

61 (42.1)

Too much effort needed

54 (37.2)

Efﬁcacy concerns

40 (27.6)

Safety concerns

20 (13.8)

Fear of side effects

17 (11.7)

Do not know enough to answer

17 (11.7)

Other

4 (2.8)

Abbreviation: SCT, scalp cooling therapy.
a
Providers were asked to rank the top 3 reasons they do not initiate discussions with patients about SCT and are not in favor of SCT.
b
All providers except those who answered that they always initiate discussions with patients about SCT were asked this question (n 5 131).
c
All providers except those who answered that they always are in favor of SCT were asked this question (n 5 84).
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